Immix Biopharma (NASDAQ: IMMX)

Last close As at 25/12/2024

USD2.17

−0.05 (−2.25%)

Market capitalisation

USD60m

Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis and multiple myeloma, with plans to expand to autoimmune indications.

Latest Insights

View More

Healthcare | Flash note

Immix Biopharma — US CAR-T trial progresses to dose expansion

Healthcare | Update

Immix Biopharma — Full steam ahead with US CAR-T trial

Healthcare | Flash note

Immix Biopharma — US$8m grant to advance novel CAR-T treatment

Healthcare | Flash note

Immix Biopharma — US CAR-T trial commences patient dosing

Scientist using protective robber gloves for handling substances and experiments

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Dr Ilya Rachman

    CEO

  • Gabriel Morris

    CFO

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free